Hercules Capital, Inc. Q4 FY2024 earnings call

Key Highlights - 2024 was a year of record operating performance with records in total gross fundings, total investment income, and net investment income. - Celebrated 20 years of investment activity with cumulative debt commitments surpassing $20 billion. - Q4 originations were driven by technology and life sciences teams, with 67% of fundings to tech and 42% to life sciences. - Exit activity in 2024 was healthy with thirteen portfolio companies announcing or completing M&A events. - Strong liquidity position with over $1.1 billion across the platform, and GAAP leverage under 90%.

In 2024, Hercules Capital, Inc. achieved record performance. Total gross fundings for the year were $1.81 billion, a 13% year-over-year increase. Total investment income was $493.6 million, a 717.1% year-over-year increase. Net investment income was $325.8 million, a 7.2% year-over-year increase. Platform AUM was approximately $4.8 billion, an increase of over 14% year over year. In Q4 2024, total gross debt and equity commitments were over $619 million, and gross fundings were over $468 million. Approximately 67% of Q4 fundings were to technology companies, while approximately 42% of new commitments were to life sciences companies.

Forward-Looking Statements - Anticipate higher market and macro volatility in 2025 but a more favorable new business landscape, especially for growth stage companies. - Intend to manage the business defensively while maintaining flexibility to seize market opportunities, including enhancing liquidity and tightening credit screens. - Expect Q1 2025 prepayments in the range of $100 million to $200 million. - Core yield guidance for Q1 2025 is between 12.25% and 12.75%.

Risks - Market and macro volatility due to changes in administration and global geopolitical environment. - Concerns about venture capital investors being more sensitive to valuations, potentially affecting companies that raised equity at inflated valuations in the last 2-3 years in raising new capital. - Uncertainty regarding the ability of current syndicates to support existing portfolio companies if valuation concerns persist.

Q: Can 2025 end up being another record year for origination activity?

A: Scott Bluestein stated if credit quality is there, they are hopeful 2025 could be another record year, with a strong start in Q1 having closed $250.2 million of new commitments and having $578.5 million in pending commitments.

Q: Talk about the RIA fundraising and earnings attribution?

A: Scott Bluestein mentioned the private credit fund business is growing, but no disclosure on the next fund yet. Seth Meyer noted dividend expectations from the RIA are reflective of earnings growth but wouldn't foresee impact on 2025.

Q: Detail credit quality drivers of realized losses and views on credit going forward?

A: Seth Meyer and Scott Bluestein said realized losses were due to convoy workout and a biotech company bankruptcy. Grade four credits increased slightly, with teams working with affected companies. Concerns about VC investors being sensitive to valuations affecting portfolio companies.

Q: Core yields and deployment assumptions?

A: Scott Bluestein said they're originating in 11.5%-13% range, expecting core yields to stabilize in 12% range and able to hit funding objectives while maintaining target.

Q: Leverage increase and impact on yield compression?

A: Scott Bluestein said being under-levered with liquidity gives competitive advantage to offset yield compression, intending to be more aggressive on leverage this year.

Q: VC syndicates sensitivity to valuations and Palantir impact?

A: Scott Bluestein said VC investors are more sensitive to valuations, affecting companies with inflated valuations. Palantir was a big driver of realized gains in Q4, with roughly $15 million in realized gains from that investment.